L

    Liminatus Pharma, Inc. Class A Common Stock (LIMN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.86
    -0.37 (-8.75%)

    Market Cap: $5.68M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.03N/AN/ABeat-112.3%
    Mar 26
    		$-1.56N/AN/ABeat-1200.6%
    Dec 25
    		$-15.09N/AN/ABeat-145.9%
    Sep 25
    		$-0.07$0.00N/AMiss+98.4%
    Jun 25
    		$0.24N/AN/ABeat+106.5%
    Mar 25
    		$-0.12N/AN/ABeat+98.0%
    Dec 24
    		$-6.14N/AN/ABeat-84.3%
    Sep 24
    		$-4.48N/AN/ABeat-124.9%
    Jun 24
    		$-3.72N/AN/ABeat-365.5%
    Mar 24
    		$-5.90N/AN/ABeat-7462.1%
    Dec 23
    		$-3.33N/AN/ABeat-5102.8%
    Sep 23
    		$-1.99N/AN/ABeat-2590.9%
    Jun 23
    		$1.40N/AN/ABeat+1173.9%
    Mar 23
    		$-0.08N/AN/ABeat-680.0%
    Dec 22
    		$-0.06N/AN/ABeat+83.5%
    Sep 22
    		$0.08N/AN/ABeat-60.0%
    Jun 22
    		$0.11N/AN/ABeat+283.3%
    Mar 22
    		$-0.01N/AN/ABeat-
    Dec 21
    		$-0.39N/AN/ABeat-
    Sep 21
    		$0.20N/AN/ABeat-
    Jun 21
    		$-0.06N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.23EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE0.00%ROIC-247.19%
    Financial Health
    Debt/Equity4.80xInterest Coverage-0.74x
    Current Ratio1.12xQuick Ratio1.12x
    Trading Statistics
    Beta0.74Avg Volume30.10M
    52-Week High$154.5052-Week Low$4.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.91
    SMA 20$5.44
    SMA 50$5.63
    SMA 200$4.21
    EMA 10$4.76
    EMA 20$5.18
    EMA 50$5.73
    EMA 200$5.40

    MACD

    Line: -0.45Signal: -0.24Hist: -0.20

    ADX

    ADX: 47.4+DI: 7.8-DI: 2.4

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down32.0
    PSAR$1.36

    Bollinger Bands

    Upper Band$7.42
    Lower Band$3.45
    %B Position7306%(Upper)
    Band Width0.10

    RSI (14-Day)

    Neutral
    34.8

    Momentum Oscillators

    Stoch %K70.3
    Stoch %D73.2
    Williams %R-34.9
    ROC (10d)-45.4%
    Momentum-3.21
    CCI (20d)59.7
    MFI (14d)96.5

    Volatility Measures

    ATR (14d)$3.71(96.1%)
    StdDev (20d)0.99
    Hist Vol178.5%(High)

    Volume Flow

    VWAP$3.97
    OBV2.4B
    AD Line902.6B
    CMF (20d)341.036

    Volume Metrics

    Avg Vol (20d)30.5M
    Vol Ratio0.0x(Low)
    VWMA (20d)$7.38

    Pivot Points

    R3$5.08
    R2$4.91
    R1$4.57
    Pivot Point$4.40
    S1$4.06
    S2$3.89
    S3$3.55

    Advanced Oscillators

    TSI-14.83
    Ultimate Osc49.7
    KST-104.49

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0N/A
    Cost of Revenue$0$0$-255$0$0$0N/A$0$0$0N/AN/A
    Gross Profit$0$0$255$0$0$0N/A$0$0$0N/AN/A
    Operating Expenses$1.38M$1.10M$1.15M$701,170$1.12M$264,220$1.88M$543,147$909,218$247$642,699$676,321
    R&D$600,000$400,000$0$0$0$0$0$357,066$714,134$0$715,000$0
    SG&A$778,908$700,898$0$701,170$1.12M$264,220$0$186,081$195,084$0$47,000$0
    Operating Income$-1,378,908$-1,100,898$-1,148,176$-701,170$-1,118,211$-264,220$-1,877,341$-543,147$-909,218$-247$-642,699$-676,321
    Interest Income$8,223$0$0$0$24,383$52,206$0$34,481$25,231$0$8,000$0
    Interest Expense$18,844$18,638$7.35M$19,052$62,288$115,512$106,142$92,706$77,220$0$17,000$0
    Income Before Tax$-1,407,259$-1,123,714$-8,496,198$-1,823,351$113,287$-327,526$-1,983,483$-601,372$-961,207$-247$-472,995$-300,290
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$13,600$23,601
    Net Income$-1,407,259$-1,123,714$-8,496,198$-1,823,351$113,287$-327,526$-1,983,483$-601,372$-961,207$-247$-486,595$-323,891
    EBITDA$-1,396,170$-1,104,558$-1,147,633$-1,803,757$151,935$-264,220$-1,877,341$-543,147$-909,218$-247$-369,906$-300,290
    EBIT$-1,396,638$-1,105,076$-1,148,176$-1,804,299$151,192$-264,220$-1,877,341$-543,147$-909,218$-247N/AN/A
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about LIMN

    News

    Liminatus Pharma Engages Synex Consulting to Support Clinical Development of IBC101 CAR-T Therapy in South Korea

    Liminatus Pharma has partnered with Synex Consulting to advance the clinical development of its bivalent CAR-T cell therapy, IBC101, in South Korea. IBC101, designed to treat relapsed or refractory diffuse large B-cell lymphoma by targeting both CD19 and CD22 antigens, has received regulatory approval for a Phase 1/2a clinical study at Seoul St. Mary’s Hospital. This collaboration aims to leverage Synex's expertise in the Korean market to accelerate patient enrollment and overall program execution, expanding Liminatus's oncology pipeline.

    Quiver Quantitative•8/24/26•
    Bullish

    Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

    Liminatus Pharma (Nasdaq: LIMN) has partnered with Korea-based contract research organization Synex Consulting to advance the clinical development of IBC101, its CD19xCD22 bivalent CAR-T cell therapy for relapsed or refractory B-cell malignancies. The Ministry of Food and Drug Safety (MFDS) in South Korea has authorized a Phase 1/2a trial for IBC101, with Seoul St. Mary's Hospital serving as the primary clinical site. This collaboration and authorization mark a significant step in expanding Liminatus' oncology portfolio and progressing IBC101 toward patient enrollment.

    Stock Titan•8/24/26•
    Bullish

    Price to earnings forward of Liminatus Pharma, Inc. – BOATS:LIMN

    The article displays the "Price to earnings forward" metric for Liminatus Pharma, Inc. (LIMN) on the Blue Ocean Alternative Trade System (BOATS) platform. The financial data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.

    TradingView•8/23/26•
    Neutral

    Press Releases about Liminatus Pharma, Inc. - Class A Common Stock (Nasdaq:LIMN)

    This article compiles recent press releases concerning Liminatus Pharma, Inc. (LIMN), highlighting key corporate actions and financial developments. Major announcements include a reverse stock split, transfer to the Nasdaq Capital Market, various financing activities, and updates on its oncology cell therapy pipeline and proposed mergers. The releases also cover strategic initiatives like evaluating digital asset investments and a notice of Nasdaq delisting.

    FinancialContent•8/21/26•
    Bearish

    Liminatus Pharma, Inc. Announces Reverse Stock Split of Its Common Stock

    Liminatus Pharma, Inc. (LMPN) has announced a 1-for-2,000 reverse stock split of its common stock, effective August 21, 2026. This action is intended to increase the per-share trading price to meet Nasdaq's minimum bid price requirement. Shareholders will receive one new share for every 2,000 shares currently held, with fractional shares being rounded up to the nearest whole share.

    Moomoo•8/19/26•
    Neutral

    Frequently Asked Questions About LIMN

    Does LIMN pay dividends?
    Liminatus Pharma, Inc. Class A Common Stock (LIMN) does not currently pay a regular dividend.
    What is LIMN's market cap?
    Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a market capitalization of $5.68M with a current stock price of $3.86.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In